SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRANCHINI, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.856
EU - Europa 2.209
AS - Asia 1.336
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
SA - Sud America 5
Totale 8.433
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.826
IT - Italia 1.143
CN - Cina 615
SG - Singapore 338
PL - Polonia 255
DE - Germania 212
UA - Ucraina 190
TR - Turchia 161
GB - Regno Unito 115
ID - Indonesia 93
SE - Svezia 84
FI - Finlandia 61
BE - Belgio 29
CA - Canada 29
CZ - Repubblica Ceca 25
VN - Vietnam 24
HK - Hong Kong 23
IN - India 19
FR - Francia 16
IR - Iran 16
RO - Romania 15
DK - Danimarca 14
NL - Olanda 14
NO - Norvegia 12
JP - Giappone 11
EU - Europa 10
TW - Taiwan 10
IQ - Iraq 8
AU - Australia 7
BR - Brasile 5
CH - Svizzera 5
KR - Corea 5
PT - Portogallo 4
ET - Etiopia 3
GE - Georgia 3
GR - Grecia 3
IE - Irlanda 3
NG - Nigeria 3
PK - Pakistan 3
RU - Federazione Russa 3
AT - Austria 2
ES - Italia 2
IL - Israele 2
KE - Kenya 2
LT - Lituania 2
MY - Malesia 2
PH - Filippine 2
DZ - Algeria 1
MX - Messico 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 8.433
Salva come PNG Salva come JPEG
Città #
Chandler 570
Fairfield 504
Woodbridge 441
Ferrara 322
Ann Arbor 277
Ashburn 269
Singapore 266
Houston 264
Warsaw 254
Wilmington 220
Jacksonville 215
Seattle 206
Cambridge 173
New York 125
Izmir 119
Princeton 118
Nanjing 101
Jakarta 91
Shanghai 90
Dearborn 88
Milan 85
Beijing 73
Bremen 62
Boardman 59
San Diego 45
Redwood City 41
Los Angeles 40
Falls Church 35
Nanchang 35
Santa Clara 35
Rome 34
Bologna 33
Shenyang 32
Brussels 24
Florence 24
Dong Ket 23
Guangzhou 21
Hebei 21
Jiaxing 21
Auburn Hills 20
London 20
San Mateo 20
Toronto 20
Helsinki 19
Brno 17
Jinan 17
Kunming 16
Changsha 15
Norwalk 15
Tianjin 14
Zhengzhou 13
Hangzhou 12
Washington 12
Hong Kong 11
Mountain View 11
Ningbo 11
Praia A Mare 10
Frankfurt am Main 9
Monmouth Junction 9
Piemonte 9
Augusta 8
Des Moines 8
Duncan 8
Ferrara di Monte Baldo 8
Hefei 8
Munich 8
Oslo 8
Baghdad 7
Bari 7
Hounslow 7
Verona 7
Andover 6
Arona 6
Chicago 6
Leawood 6
Orange 6
Ottawa 6
Redmond 6
Albissola Marina 5
Catania 5
Haikou 5
Olomouc 5
Padova 5
Rochester 5
Taipei 5
Addison 4
Amsterdam 4
Atlanta 4
Bangalore 4
Cagliari 4
Calderara di Reno 4
Calvisano 4
Castelcovati 4
Civitanova Marche 4
Copenhagen 4
Dallas 4
Fuzhou 4
Gragnano 4
Louvain 4
Naples 4
Totale 5.977
Salva come PNG Salva come JPEG
Nome #
La sanificazione delle degenze ospedaliere: nuove strategie per la riduzione delle infezioni correlate all’assistenza sanitaria 271
La sanificazione delle degenze ospedaliere: nuove strategie a supporto della riduzione delle infezioni correlate all’assistenza sanitaria 270
Impact of a Probiotic-Based Cleaning Intervention on the Microbiota Ecosystem of the Hospital Surfaces: Focus on the Resistome Remodulation 222
The carboxyl-terminal region of coagulation factors: role in biosynthesis and function of FVII and FX 198
Il sistema di sanificazione PCHS Probiotic Cleaning Hygien System: risultati delle indagini sperimentali in vitro e in campo 183
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 164
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 163
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 155
PCHS (Probiotic Hygiene Cleaning System) Protocol: reduction of hospital environmental impact with a new and innovative technology for cleaning in Ferrara University Hospital 148
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 147
The carboxyl-terminal region is NOT essential for secreted and functional levels of coagulation factor X 144
Hard surface biocontrol in hospitals using microbial-based cleaning products 140
Chronic sleep deprivation markedly reduces coagulation factor VII expression 136
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 135
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 126
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 122
Reduction of the microbial load on hospital surfaces through probiotic-based cleaning procedures: a new strategy to control nosocomial infections 122
Activation of a cryptic splice site in a potentially lethal coagulation defect accounts for a functional protein variant 122
Asymmetric processing of mutant factor X Arg386Cys reveals differences between intrinsic and extrinsic pathway activation 121
Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency 119
The carboxyl-terminal region is not essential for secreted and functional levels of coagulation factor X 119
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 111
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 107
Factor II Activity is Similarly Increased in Patients with Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele 104
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 104
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 103
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 103
I probiotici: aspetti generali e valutazioni sulla sicurezza d’impiego 100
F9 genotype and PK hemophilia B international study (GEPKHIS) 99
Characterization of the intracellular signalling capacity of natural FXa mutants with reduced pro-coagulant activity 99
Replacement of the Y450 (c234) phenyl ring in the carboxyl-terminal region of coagulation factor IX causes pleiotropic effects on secretion and enzyme activity 95
1,3,8-Triazaspiro[4.5]decane Derivatives Inhibit Permeability Transition Pores through a FO-ATP Synthase c Subunit Glu119-Independent Mechanism That Prevents Oligomycin A-Related Side Effects 94
null 94
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 94
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 94
null 93
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 93
Disease-causing variants of the conserved+2T of 5 ' splice sites can be rescued by engineered U1snRNAs 93
Non-conventional therapeutic strategies for inherited disorders oh hemostasis 92
null 84
Activated factor VII: antithrombin complex plasma concentration in subjects with or without angiographically demonstrated coronary artery disease and myocardial infarction 82
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 80
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 77
Association of the homozygous nonsense mutation R402X in coagulation factor VII with asymptomatic phenotype 77
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 75
Improved intracellular processing of protein variants as a personalized therapeutic approach for Haemophilia 74
null 73
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 72
null 71
Molecular mechanisms and determinants of innovative correction approaches in coagulation factor deficiencies 70
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 67
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 66
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity 65
Characterization of PAR-mediated signaling induced by activated coagulation factor X mutants 64
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 63
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 60
A recoded view on the F9 p.Cys178Ter pathogenic mechanism 58
MOLECULAR MECHANISMS AND THERAPEUTIC APROACHES FOR RESTORATION OF mRNA TRANSCRIPTION, MATURATION AND TRANSLATION IN INHERITED COAGULATION FACTOR DEFICIENCIES 57
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 57
The F7 p.Val22Ile missense mutation affects splicing and can be counteracted by a compensatory U1snRNA 57
The carboxyl-terminal region of coagulation serine proteases: A matter of cut and change 57
The FVII R402X nonsense mutation, associated with an asymptomatic phenotype, is responsible for small amounts of circulating protein with improved coagulant activity 57
null 56
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 56
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 56
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 56
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 53
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 52
Effects of Partial Chronic Sleep Deprivation on the Mouse Blood Coagulation Cascade. 52
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 51
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 50
Exploring spontaneous readthrough over recurrent F8 nonsense mutations: potential correlation with inhibitor risk? 50
Hemostasis gene expression of the internal jugular and saphenous veins 48
Engineered transcription factors (TALE-TF) as potential therapeutic strategy for coagulation factor deficiencies caused by promoter mutations 47
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations 46
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 46
null 45
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 45
RNA-based therapeutic approaches for blood coagulation factor deficiencies caused by a splicing mutations 45
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 45
null 44
Next generation factor VIIa with enhanced half-life 44
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 43
Molecular insights into determinants of translational readthrough and implications for nonsense suppression approaches 43
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 43
Translation termination codons in protein synthesis and disease 42
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 42
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 41
Improved intracellular processing of protein variants as a personalised therapeutic approach for haemophilia 40
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 40
Genotype and PK Hemophilia B International Study (GePKHIS) - A progress Report 38
The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones 38
Academic Editor per la rivista PLoS One 36
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 35
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 35
Associate Editor per la rivista Frontiers in Genetics - sezione Genetic Disorders 34
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 33
Caratterizzazione dei determinanti molecolari del processo di soppressione di mutazioni nonsenso mediato da ribosome readthrough 33
RNA−based therapeutic approaches for blood coagulation factor deficiencies caused by splicing mutations 31
Exploring base editing for the correction of nonsense mutations in hemophilia B 31
Totale 8.327
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.774
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 247
Totale 46.021
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020973 0 0 0 0 122 242 151 126 123 125 55 29
2020/20211.400 64 55 53 92 61 100 255 176 82 198 179 85
2021/20221.181 170 139 37 36 82 72 49 48 35 84 74 355
2022/20231.242 132 144 50 174 179 158 77 79 135 11 58 45
2023/2024856 63 67 44 32 54 156 41 62 29 33 44 231
2024/2025649 102 78 302 108 59 0 0 0 0 0 0 0
Totale 8.788